The Capacity Building strategy aims to improve capacities of PLHIV and HepC, the most vulnerable populations and Latin-American activists in general. To achieve this, FGEP carries out national and international workshops and coordinates an online course called ‘Towards the Sustainability of Treatments for HIV/AIDS and Universal Access to HepC Treatments’ in collaboration with RedLAM partner organizations.


Online course: ‘Towards the Sustainability of Treatments for HIV/AIDS and Universal Access to HepC Treatments’

The online course is address to activists, members of social organizations, students, teachers, academics from more than 12 Latin-American countries, including Argentina, Brazil, Colombia, Guatemala, Dominican Republic and Paraguay.

The course’s goals are:

  • Provide information to participants about IP & Access to medicines.
  • Increase participants’ capacities regarding IP and treatments for HIV and Hepatitis C in order to implement it in their countries.
  • Build participants’ capacities to promote mobilization that could improve public policies related to access to medicines.

The course focuses on the following subjects:

  • Rights to health and medicines.
  • Protection of IP rights and public health safeguards.
  • TRIPS and Doha Declaration. TRIPS and public health.
  • Public health safeguards.
  • Requirements and patentability criteria.
  • Public health safeguards: compulsory licenses and its use in Brazil and Ecuador.
  • Patented and generic medicines.
  • TRIPS-PLUS measures. FTA.
  • Advocacy strategies


Regional forums

In December 2014, FGEP organized the ‘Regional Forum on Medicines Local Production Policies. Debating strategies in Latin-America’. This forum, that took place from 9 to 12, had the following goals:

  • To know about the national regulatory frameworks of generic medicines production.
  • To know technical capacities of latin american countries regarding local production of medicines, including biotechnological medicines.
  • To increase capacity to allow the analysis of local production of medicines as well as to analyze capacity for production and innovation.
  • To identify which essential medicines are available in the market and analyze international offer of generic versions to visualize how the competition reduces prices and which is the role of local production in that reduction.
  • To discuss strategies and program joint interventions in order to make access to treatments possible for all.